title: Genetic testing for breast cancer predisposition in 1999: which molecular strategy and which family criteria?
authors.forename: D
authors.initials: D
authors.lastname: Stoppa-Lyonnet
authors.forename: M
authors.initials: M
authors.lastname: Caligo
authors.forename: D
authors.initials: D
authors.lastname: Eccles
authors.forename: D G
authors.initials: DG
authors.lastname: Evans
authors.forename: N E
authors.initials: NE
authors.lastname: Haites
authors.forename: N S
authors.initials: NS
authors.lastname: Hodgson
authors.forename: P
authors.initials: P
authors.lastname: Møller
authors.forename: P J
authors.initials: PJ
authors.lastname: Morrison
authors.forename: C M
authors.initials: CM
authors.lastname: Steel
authors.forename: H F
authors.initials: HF
authors.lastname: Vasen
authors.forename: J
authors.initials: J
authors.lastname: Chang-Claude
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics*; D004252:DNA Mutational Analysis / Q000379:methods; D005060:Europe / Q000453:epidemiology; D005260:Female; D019398:Genes, BRCA1; D005817:Genetic Counseling; D018740:Genetic Heterogeneity; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006801:Humans; D008957:Models, Genetic; D009386:Neoplastic Syndromes, Hereditary / Q000453:epidemiology / Q000235:genetics*; D009857:Oncogenes; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity